Skip to main content
Journal cover image

ACR Appropriateness Criteria® thyroid carcinoma.

Publication ,  Journal Article
Salama, JK; Golden, DW; Yom, SS; Garg, MK; Lawson, J; McDonald, MW; Quon, H; Ridge, JA; Saba, N; Smith, RV; Worden, F; Yeung, AR; Beitler, JJ
Published in: Oral Oncol
June 2014

The ACR Head and Neck Cancer Appropriateness Criteria Committee reviewed relevant medical literature to provide guidance for those managing patients with thyroid carcinoma. The American College of Radiology Appropriateness Criteriaare evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Thyroid cancer is the most common endocrine malignancy in the United States, most often presenting as a localized palpable nodule. Surgery is the mainstay of treatment for WDTC, with most patients undergoing complete resection of their disease having good outcomes. Following surgery thyroxine supplementation should begin to suppress TSH, which unchecked can stimulate residual disease and/or metastatic progression, Adjuvant treatment with radioactive iodine (RAI) using iodine-131 ((131)I) is frequently used for diagnostic and therapeutic purposes. The use of EBRT for thyroid cancer has not been tested in well-designed, randomized, controlled trials and should, therefore, be considered on a case-by-case basis. Chemotherapy plays a minimal role in the management of WDTC. Novel biologic agents, such as systemic therapy options, are being actively investigated, and patients with metastatic thyroid cancer that is not iodine avid should be encouraged to enroll in clinical trials exploring novel systemic agents.

Duke Scholars

Published In

Oral Oncol

DOI

EISSN

1879-0593

Publication Date

June 2014

Volume

50

Issue

6

Start / End Page

577 / 586

Location

England

Related Subject Headings

  • Thyroid Neoplasms
  • Oncology & Carcinogenesis
  • Humans
  • Dentistry
  • Consensus
  • 3211 Oncology and carcinogenesis
  • 3203 Dentistry
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis
  • 1105 Dentistry
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Salama, J. K., Golden, D. W., Yom, S. S., Garg, M. K., Lawson, J., McDonald, M. W., … Beitler, J. J. (2014). ACR Appropriateness Criteria® thyroid carcinoma. Oral Oncol, 50(6), 577–586. https://doi.org/10.1016/j.oraloncology.2013.12.004
Salama, Joseph K., Daniel W. Golden, Sue S. Yom, Madhur Kumar Garg, Joshua Lawson, Mark W. McDonald, Harry Quon, et al. “ACR Appropriateness Criteria® thyroid carcinoma.Oral Oncol 50, no. 6 (June 2014): 577–86. https://doi.org/10.1016/j.oraloncology.2013.12.004.
Salama JK, Golden DW, Yom SS, Garg MK, Lawson J, McDonald MW, et al. ACR Appropriateness Criteria® thyroid carcinoma. Oral Oncol. 2014 Jun;50(6):577–86.
Salama, Joseph K., et al. “ACR Appropriateness Criteria® thyroid carcinoma.Oral Oncol, vol. 50, no. 6, June 2014, pp. 577–86. Pubmed, doi:10.1016/j.oraloncology.2013.12.004.
Salama JK, Golden DW, Yom SS, Garg MK, Lawson J, McDonald MW, Quon H, Ridge JA, Saba N, Smith RV, Worden F, Yeung AR, Beitler JJ. ACR Appropriateness Criteria® thyroid carcinoma. Oral Oncol. 2014 Jun;50(6):577–586.
Journal cover image

Published In

Oral Oncol

DOI

EISSN

1879-0593

Publication Date

June 2014

Volume

50

Issue

6

Start / End Page

577 / 586

Location

England

Related Subject Headings

  • Thyroid Neoplasms
  • Oncology & Carcinogenesis
  • Humans
  • Dentistry
  • Consensus
  • 3211 Oncology and carcinogenesis
  • 3203 Dentistry
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis
  • 1105 Dentistry